Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CanAroma: Topical Cannabinoids for AIMSS
NCT05935891Phase 1Completed
- Sponsor
- University of Minnesota
- Start
- Feb 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of Zygel and dronabinol in Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) (2 arms), sponsored by University of Minnesota. Primary endpoints: Subject Recruitment Rate at 4 weeks and Subject Retention Rate at 4 weeks. Started Feb 2023; status: completed.
02
Drugs
Zygeldronabinol
03
Conditions
Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS)
Beyond the preview
Go deeper on NCT05935891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05935891.